Market Place
Sourcing Support
Orum Therapeutics Submits Registration Statement for KOSDAQ Listing
02 Oct 2024 //
BUSINESSWIRE
Vertex mines for more gene editing riches with $15M Orum licensing deal
17 Jul 2024 //
FIERCE BIOTECH
Orum Therapeutics And Vertex Sign Multi-Target License Agreement
16 Jul 2024 //
BUSINESSWIRE
Bristol Myers buys Orum`s blood cancer therapy for up to $180 mln
07 Nov 2023 //
REUTERS
Orum Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb
06 Nov 2023 //
BUSINESSWIRE
Orum Unveils New Program at AACR 2023, Cbl-b Inhibitor-PD-1 Conjugate
18 Apr 2023 //
BUSINESSWIRE
Orum Therapeutics Announces Three Presentations at AACR 2023
14 Mar 2023 //
BUSINESSWIRE
Orum Therapeutics Presents Positive Preclinical Data of ORM-6151 at ASH
10 Dec 2022 //
BUSINESSWIRE
Orum doses first subject in Phase I solid tumour drug trial
01 Nov 2022 //
CLINICALTRIALSARENA
Orum Therapeutics Announces First Patient Dosed in Phase 1 Trial of ORM-5029
31 Oct 2022 //
BUSINESSWIRE
Orum Therapeutics to Participate at Investor Conferences in September
06 Sep 2022 //
BUSINESSWIRE
Orum Tx Presents Preclinical Data at AACR 2022 Highlighting ORM-5029
08 Apr 2022 //
BUSINESSWIRE
Orum Therapeutics Announces Formation of Scientific Advisory Board
04 Apr 2022 //
BUSINESSWIRE
Orum Tx to Present Preclinical Data for ORM-5029 at AACR 2022
08 Mar 2022 //
BUSINESSWIRE
Orum Therapeutics to Participate in February Investor Conferences
10 Feb 2022 //
BUSINESSWIRE
Orum Therapeutics Appoints Olaf Christensen, as Chief Medical Officer
06 Oct 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.